InVitria to Sponsor Gladstone Institutes’ Life Science Product ShowInVitria will showcase its cell culture product offering targeting stem cell and regenerative medicine researchers. Fort Collins, CO July 24, 2009 – InVitria will serve as a sponsor of the 2009 Gladstone Institutes’ Life Science Product Show on July 28, 2009 at the UCSF Mission Bay Campus in San Francisco, CA. InVitria manufactures a line of animal free and defined media components that provide optimal performance and regulatory efficiency for stem cell and regenerative medicine applications. The InVitria line of cell culture media components have been designed and manufactured for use in both research and commercial scale applications. These components give scientists the confidence and consistency they desire while optimizing cell performance. “Being a part of the Gladstone Institute’s Life Science Product Show is an excellent opportunity for InVitria to meet with leading researchers in stem cell and regenerative medicine,” said Brandy Sargent, InVitria Account Manager. “InVitria is excited to have the opportunity to develop partnerships with Gladstone researchers and we look forward to sharing the many benefits of InVitria’s cell culture supplements, namely safety, consistency and optimal performance.” InVitria’s products include Cellastim, Lacromin and Optiferrin. These products have been shown to improve performance of many cell lines used in stem cell and regenerative medicine applications including embryonic, induced pluripotent (iPS), mesenchymal, neural, cardiac, osteoblast, keratinocyte and fibroblast. These products are unrivaled in their performance and ability to enhance cell growth while maintaining undifferentiated cells. InVitria’s cell culture supplements also eliminate the need for fetal bovine serum (FBS), plasma-derived human serum albumin (pHSA) and knockout serum replacement (KSR). About InVitria (www.InVitria.com) For more information about InVitria’s product line, contact us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call 1-800-916-8311.
|
-
Blog: The Cell Culture Dish
Strategies for Improving Viral Yield in Vaccine Manufacturing
A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More
-
Latest News
InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference
March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more
